Chardan analyst Keay Nakae raised the firm’s price target on ProQR Therapeutics to $2.50 from $2 and keeps a Buy rating on the shares post the Q4 report. The analyst says the company’s drugs have advanced closer to the clinic.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PRQR:
- ProQR Announces Year End 2023 Operating and Financial Results
- ProQR Therapeutics BV (PRQR) Q4 Earnings Cheat Sheet
- ProQR Therapeutics announces Japanese Axiomer patent upheld
- Biotech Alert: Searches spiking for these stocks today
- ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024